Lupin jumps on getting USFDA`s tentative approval for DETAF Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 740.30, up by 5.90 points or 0.80% from its previous closing of Rs. 734.40 on the BSE.
The scrip opened at Rs. 730.05 and has touched a high and low of Rs. 740.30 and Rs. 727.55 respectively. So far 5832 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 922.50 on 01-Feb-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 752.90 and Rs. 727.55 respectively. The current market cap of the company is Rs. 33228.66 crore.
The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 43.36% and 9.53% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets. This product would be manufactured at Lupin’s Nagpur facility in India. DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- & middle-income countries.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
